Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to ...

The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon's confirmation hearing is canceled ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...